Novel compounds demonstrate potential as ERK5 inhibitors in cancer treatment, suggesting effective therapeutic options.
Provided herein are novel 3-aza-bicyclo[3.3.0]octanecompounds as ERK5 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
No takes yet. Share an insight, caveat, or question.
Ram W. Sabnis (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: